Use of Flurbiprofen to Inhibit Corneal Neovascularization

Cooper, Charles; Bergamini, Michael V.W.; Leopold, Irving H.

doi:10.1001/archopht.1980.01020031092017

Cited by 46 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Many nonsteroidal anti-inflammatory drugs (NSAIDs) have been tested as ocular antiinflammatory agents [2][3][4] so as to diminish the well-documented ocular side effects caused by corticosteroids. Ketorolac tromethamine (KT), an aryl-acetic acid NSAID is nonirritating to the eye at 0.5% wt/vol concentration.…”

Section: Introductionmentioning

confidence: 41%

In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: A technical note

Malhotra

Majumdar

2005

AAPS PharmSciTech

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 41%

In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: A technical note

Malhotra

Majumdar

2005

AAPS PharmSciTech

View full text Add to dashboard Cite

“…Many NSAIDs have been tested as ocular anti-inflammatory agents so as to diminish the well-documented ocular side effects caused by corticosteroids [Cooper et al, 1980;Searle et al, 1990]. Ketorolac tromethamine (KT) is a potent and effective aryl-acetic acid NSAID and is nonirritating to the eye at 0.5% w/v concentration [Mahoney and Waterbury, 1983].…”

Section: Introductionsupporting

confidence: 44%

Sustained ophthalmic in situ gel of ketorolac tromethamine: rheology and in vivo studies

Manjappa¹,

Nanjwade²,

Manvi³

et al. 2009

Drug Development Research

View full text Add to dashboard Cite

Most ocular diseases are treated with topical eye drops. The poor bioavailability and therapeutic response exhibited by these conventional eye drops due to rapid precorneal elimination of the drug may be overcome by the use of in situ gelling systems that are instilled as drops into the eye and undergo a sol-to-gel transition in the cul-de-sac. The present work describes the formulation and evaluation of an ophthalmic delivery system of the nonsteroidal anti-inflammatory drug (NSAID), ketorolac tromethamine, based on the concept of pH-triggered in situ gelation. Polyacrylic acid (Carbopol s 934) was used as the gelling agent in combination with hydroxypropylmethylcellulose (Methocel E15LV), which acted as a viscosity enhancer. The prepared formulations were characterized for clarity, pH, drug content, rheology, and in vivo drug release. Clarity, pH, and drug content of the developed formulations were found to be satisfactory. The developed formulation showed pseudo-plastic rheology. The formulation with benzalkonium chloride and edetate disodium improved the rate of corneal absorption but not the extent. The developed formulation is a viable alternative to conventional eye drops by virtue of its ability to enhance bioavailability through its longer precorneal residence time and ability to sustain drug release. Also importantly is the ease of instillation afforded and decreased frequency of instillation resulting in better patient acceptance. Drug Dev Res 70 : 417-424, 2009.

show abstract

“…In silver nitrate cauterization and anterior chamber alloxan models of corneal neovascularization an inhibitory effect of topically applied flurbiprofen has been observed with concentrations of 0.01% (Cooper et al, 1980). Corneal neovascularization induced by contact lens wear in rabbits was significantly suppressed by 0.03% flurbiprofen (Duffin et al, 1982).…”

Section: Introductioncontrasting

confidence: 38%